ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

被引：0

作者：

Hillmen, Peter

Brown, Jennifer R.

Byrd, John C.

Eichhorst, Barbara

Lamanna, Nicole

O'Brien, Susan Mary

Qiu, Lugui

Paik, Jason C.

Hilger, James D.

Huang, Jane

Tam, Constantine S.

机构：

[1] St James Univ Hosp, Leeds, W Yorkshire, England

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[4] Univ Cologne, Dept Internal Med 1, Cologne, Germany

[5] Columbia Univ, Irving Comprehens Canc Ctr, New York, NY USA

[6] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA

[7] Chinese Acad Med Sci, Peking Union Med Coll, Tianjin, Peoples R China

[8] BeiGene USA Inc, San Mateo, CA USA

[9] Univ Melbourne, St Vincents Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7572

引用

页数：1